MARKET

MORF

MORF

Morphic Holding
NASDAQ

Real-time Quotes | Nasdaq Last Sale

20.01
-0.77
-3.71%
Closed 16:19 06/01 EDT
OPEN
20.40
PREV CLOSE
20.78
HIGH
20.98
LOW
19.56
VOLUME
51.62K
TURNOVER
--
52 WEEK HIGH
33.50
52 WEEK LOW
9.90
MARKET CAP
612.36M
P/E (TTM)
-11.0066
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average MORF stock price target is 29.67 with a high estimate of 31.00 and a low estimate of 28.00.

EPS

MORF News

More
Morphic to Present at the Jefferies Virtual Healthcare Conference
Morphic Therapeutic (MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced that the Morphic executive team is scheduled to make a presentation at the
GlobeNewswire · 6d ago
Morphic (MORF) Presents At Bank of America Healthcare Virtual Conference 2020 - Slideshow
Seeking Alpha - Article · 05/14 17:29
Morphic Holding Q1 EPS $(0.550) Up From $(2.770) YoY
Morphic Holding (NASDAQ:MORF) reported quarterly losses of $(0.550) per share. This is a 80.14 percent increase over losses of $(2.770) per share from the same period last year.
Benzinga · 05/06 20:22
Morphic Announces Corporate Highlights and First Quarter 2020 Financial Results
Data presented at ECCO Congress support MORF-057 in IBD; IND on track for mid-year Recent executive appointments of Peter Linde, M.D., as CMO and Marc Schegerin, M.D., as.
GlobeNewswire · 05/06 20:05
Morphic Therapeutic to Present at the BofA Securities 2020 Health Care Conference
Morphic Therapeutic (MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced that the Morphic executive team is scheduled to make a virtual presentation
GlobeNewswire · 04/29 20:15
Morphic Announces Appointment of Marc Schegerin, M.D., as Chief Financial Officer and Chief Operating Officer
GlobeNewswire · 04/07 13:00
Morphic Therapeutic Names Marc Schegerin CFO, COO
Benzinga · 04/07 12:15
Morphic Announces Appointment of Peter G. Linde, M.D., as Chief Medical Officer
GlobeNewswire · 03/17 13:00

Industry

Pharmaceuticals
-1.07%
Pharmaceuticals & Medical Research
-0.77%

Hot Stocks

Symbol
Price
%Change

About MORF

Morphic Holding, Inc is a biopharmaceutical company. The Company is engaged in discovering and developing a pipeline of potentially first-in-class oral small-molecule integrin therapeutics. Integrins are a target class with multiple approved injectable blockbuster drugs for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. The Company is advancing its preclinical pipeline, including its lead wholly-owned program for alpha 4 and beta 7-specific integrin inhibitors affecting inflammation into clinical development for the treatment of inflammatory bowel disease (IBD). It is also developing MORF-720, a selective oral specific integrin inhibitor into clinical development for the treatment of idiopathic pulmonary fibrosis (IPF).
More

Webull offers kinds of Morphic Holding Inc stock information, including NASDAQ:MORF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MORF stock news, and many more online research tools to help you make informed decisions.